Quinshell 300 Injection contains Quinine 300mg, an antimalarial intravenous agent indicated for the treatment of malaria and symptomatic relief of fever caused by Plasmodium species. It helps rapidly reduce parasite load and control high fever effectively.
Quinine works by disrupting the parasite’s ability to metabolize hemoglobin, leading to parasite death in the bloodstream. Its intravenous formulation ensures faster therapeutic effect, making it suitable for severe malaria cases and hospitalized patients.
For distributors and healthcare suppliers, Quinshell 300 Injection is a high-demand antimalarial therapy product, commonly used in hospitals, emergency care units, endemic regions, and government malaria programs. Seasonal malaria prevalence ensures continuous demand throughout the year.
Adding Quinshell 300 Injection to your antimalarial therapy segment creates strong opportunities in hospital supply chains, clinics, export markets, and third-party manufacturing. Its clinical reliability, prescriber trust, and essential role in malaria management make it a valuable addition to pharmaceutical distribution portfolios.